We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
3-in-1 Vaccine Against Traveller’s Diarrhea
News

3-in-1 Vaccine Against Traveller’s Diarrhea

3-in-1 Vaccine Against Traveller’s Diarrhea
News

3-in-1 Vaccine Against Traveller’s Diarrhea

Photo credit: Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "3-in-1 Vaccine Against Traveller’s Diarrhea"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A first-ever vaccine designed to deliver a one-two-three punch against the main causes of traveller’s diarrhea worldwide may result from new research published by a University of Guelph chemist.

Prof. Mario Monteiro says his novel three-in-one approach to developing a new vaccine could also save lives in developing countries, where it’s estimated that these three common pathogens kill more than 100,000 children under age five each year.

His research was recently published in the journal Vaccine.

The paper discusses Monteiro’s conjugate vaccine that yokes together proteins from pathogenic E. coli with sugars from Shigella and Campylobacter jejuni. All three bugs are major causes of bacterial diarrhea globally.

In tests with mice, the vaccine provided immunity against all three pathogens.

No licensed vaccines exist against any of these pathogens. A sugar-based vaccine developed by Monteiro in 2009 against campylobacter alone is currently undergoing human trials but is still an estimated decade away from potential release.

He said this new three-in-one approach may ultimately overtake that earlier single-target vaccine, although any new vaccine may take decades to test and release. “We’re targeting three pathogens at the same time,” he said. “Instead of three shots, maybe you only need one.”

As with the earlier campylobacter vaccine, this new method has been patented by U of G and the United States Naval Medical Research Center, which funded the research.

Monteiro said further research is needed to determine the optimum amounts of protein and sugars in the vaccine and to make the vaccine more efficient.

He worked on the project with former post-doc Zuchao Ma and former graduate students Brittany Pequegnat and Eman Omari, along with U.S. navy researchers.

This article has been republished from materials provided by the University of Guelph. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Laird, R. M., Ma, Z., Dorabawila, N., Pequegnat, B., Omari, E., Liu, Y., . . . Guerry, P. (2018). Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella. Vaccine. doi:10.1016/j.vaccine.2018.09.052

Advertisement